The Nootropic Research Hub covers the science behind cognitive and neurological research compounds — including racetams, peptide nootropics, cholinergics, adaptogens, and mitochondria-targeted compounds. All content is educational and research-referenced.
How to Use This Nootropic Research Hub
Use this nootropic research hub to compare compounds by class, mechanism, and evidence level before opening an individual profile. Start with the compound database when you need a broad index, then follow the linked research articles for deeper literature context. Human clinical data, animal studies, and in-vitro findings are labeled separately because they support different conclusions. When a profile discusses an approved or registered medicine, that status is identified separately from investigational compounds and supplements. This structure keeps each nootropic research summary tied to its available evidence and helps readers distinguish established observations from early hypotheses. This is an educational starting point, not a dosing guide or treatment recommendation.
What Are Nootropics?
The term “nootropic” was coined by Romanian chemist Corneliu Giurgea in 1972, who defined it as a compound that enhances learning and memory, protects the brain under adverse conditions, enhances brain function in subcortical control mechanisms, and lacks the side effect profile of typical psychotropic drugs. In common use today, “nootropic” broadly covers any compound studied for cognitive, neuroprotective, or neurological effects.
Nootropics span a wide evidence spectrum — from compounds with significant human clinical trial data (racetams, some adaptogens) to compounds with primarily animal model or in vitro data. This hub presents research with clear evidence level labeling.
Nootropic Compound Profiles
Peptide Nootropics
- Selank — Synthetic heptapeptide analog of tuftsin; studied for anxiolytic and nootropic effects in Russian research
- Semax — ACTH 4-10 analog studied for neuroprotective and cognitive effects; registered drug in Russia
- Dihexa — Angiotensin IV analog reported to potently potentiate HGF/c-Met signaling involved in synaptogenesis
- Epithalon — Tetrapeptide studied for telomerase activation and anti-aging effects in animal and some human research
- Cerebrolysin — Peptide complex derived from porcine brain protein; studied in clinical trials for stroke and Alzheimer’s disease
Racetams
- Piracetam — The original racetam; studied for cognitive effects in aging populations in multiple European trials
- Aniracetam — Fat-soluble racetam with AMPA receptor potentiation and anxiolytic properties studied in rodent models
- Phenylpiracetam — Phenyl-substituted piracetam analog with reported stimulant and cognitive-enhancing properties
- Oxiracetam — Studied for memory enhancement in clinical trials in patients with organic brain syndrome
NAD+ and Mitochondrial Nootropics
- NAD+ / NMN — NAD+ precursors studied for mitochondrial function, cognitive aging, and sirtuin activation
- SS-31 (Elamipretide) — Mitochondria-targeted peptide with neuroprotective effects studied in animal models
Adaptogens and Other Categories
- 5-Amino-1MQ — NNMT inhibitor studied for NAD+ pathway effects and metabolic function
- AICAR — AMPK activator with reported effects on metabolic and mitochondrial gene expression
Evidence Standards for Nootropics
Nootropic research quality varies enormously. Some compounds have robust human clinical trial data (piracetam has been studied in dozens of controlled trials; cerebrolysin has Cochrane-reviewed data for stroke). Others have exclusively animal model or in vitro data. All compound profiles on this site include an evidence level assessment to make this distinction clear.
Use the compound database to filter compounds by evidence level and research area. The research calculators include tools relevant for peptide and nootropic lab work.
For primary literature, browse PubMed’s nootropic-compound research results and compare study population, model, and outcome measures with the evidence level shown in each profile.
All content is for educational and research reference purposes only. Nootropic compounds vary widely in regulatory status. Nothing here constitutes medical advice or a recommendation for any compound.
Latest Nootropic Research Articles
Longevity Stacks: NAD+, Senolytics & Peptide Synergies
Evidence-graded breakdown of the longevity biology landscape and where peptides fit in the picture.
Semax, Selank, and Dihexa: What the Research Says
Three of the most-discussed nootropic peptides compared — mechanism, evidence level, and what we know from published literature.
The Biohacker’s Stack: GLP-1 + Peptides
Combination rationale, GH axis considerations, and nootropic layers — how researchers are studying these compounds together.